Recently, WixBio ND-AI-IBH Vaccine (Newcastle Disease, Influenza, and Adenovirus Triple Vaccine), an inactivated poultry vaccine, was successfully shipped to the Middle East. This cooperation marks another important milestone for Wixbio in the international veterinary market and provides a powerful disease-prevention solution for the local poultry farming industry.
Product Advantages and Features
Based on advanced cell suspension culture and prokaryotic expression technologies, the new vaccine is characterized by its high antigenic content, long immunity period, and broad applicability. Integrating the prevention of three major poultry diseases in a single dose not only simplifies the immunization procedure but also effectively reduces the stress caused by multiple chicken vaccinations. In addition, the scientifically designed immunization program ensures adequate protection for chickens of different age groups, which helps to improve the farm’s overall production performance.
A new chapter of international cooperation
With the successful delivery of this batch of vaccines, Wixbio will further strengthen its partnership with its Middle East distributors in a joint effort to improve animal healthcare in the region. In response to the unique needs of the Middle East market, the company will continue to provide technical support and service guarantees to ensure the best use of vaccines in the region. At the same time, this also reflects Wixbio’s firm commitment to actively expanding overseas markets and serving global customers.
Wide Market Prospects
최근 몇 년간 가금류 사이에서 H9 아형 조류 인플루엔자와 그룹 I 4 조류 아데노바이러스가 널리 확산되면서 가금 산업에 막대한 경제적 손실이 발생했습니다. 새로운 3종 불활화 인플루엔자 아데노바이러스 백신의 출시는 이러한 질병의 발생을 효과적으로 통제할 뿐만 아니라 농가의 비용을 절감하고 경제성을 향상시킵니다. Wixbio의 신백신은 더 많은 국가와 지역에서 이 제품을 인정함에 따라 향후 몇 년간 국제 시장에서 더욱 중요한 위치를 차지할 것으로 기대됩니다.
Wixbio는 앞으로도 업계 발전에 집중하고 혁신적인 수의 생물학적 제제를 선보여 전 세계 축산업의 건전한 발전에 기여할 것입니다.
